Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study

作者：Lu, Ju-Ming^*; Ji, Li-Nong^*; Li, Yu-Feng; Li, Quan-Min; Lin, Shan-Shan; Lv, Xiao-Feng; Wang, Li; Xu, Yuan; Guo, Xiao-Hui; Guo, Qi-Yu; Ma, Li; Du, Jin; Chen, Ying-Li; Zhao, Cui-Ling; Zhang, Qiu-Lan; She, Qi-Mei; Jiao, Xiu-Min; Lu, Mei-Hua; Pan, Rong-Qing; Gao, Ying

来源：Journal of Diabetes and Its Complications, 2016, 30(8): 1609-1613.

DOI：10.1016/j.jdiacomp.2016.07.007

• Glycated albumin
• Glycated hemoglobin
• Diabetes
• Oral hypoglycemic agents
• Fasting blood glucose

Aims: This study was to determine whether serum glycated albumin (GA) was a better indicator of glycemic control than hemoglobin A1c (HbA1c) when starting a new treatment regimen for type 2 diabetes. @@@ Methods: Newly diagnosed type 2 diabetes patients, or patients who had poor glycemic control with oral hypoglycemic agents, were enrolled at 10 hospitals in Beijing. Serum GA, HbA1c, fasting blood glucose (FBG), and C-peptide were assayed on Days 0, 14, 28, and 91 after treatment. @@@ Results: Four hundred ninety-nine patients were enrolled. Mean FBG, GA and HbA1c decreased significantly in patients at Days 14, 28, and 91. In patients with improved glycemic control, the reduction of GA and HbAl c levels was 10.5 13.3% vs. 5.1 5.4% on Day 14, 16.0 13.4% vs. 9.0 7.0% on Day 28, and 18.0 16.7% vs. 18.3 9.4% on Day 91, respectively, compared with baseline values. Changes in GA on Day 14, 28 and 91 were all closely correlated with changes in HbA1c on Day 91. Change in GA on Day 14 was correlated with treatment effectiveness evaluated by HbA1c on Day 91. @@@ Conclusions: GA may be a useful marker for assessing glycemic control at an early stage of new diabetes treatment and assist in guiding adjustments to treatment and therapy.

• 出版日期2016-11
• 单位北京市石景山医院; 中国人民解放军总医院; 中国人民解放军海军总医院; 中医学科学院; 中国中医科学院; 北京大学; 首都医科大学; 中国中医科学院广安门医院; 中国人民解放军第二炮兵总医院